Corvidane

Early Stage

Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants from NASH

Analytics

Raised to Date: Raised: $371,284

Aggregate Commitments $

Platform

Wefunder

Start Date

01/04/2022

Close Date

04/30/2022

Min. Goal

$50,000

Max. Goal

$1,000,000

Min. Investment

$100

Security Type

SAFE

Funding Type

RegCF

Series

Pre-Seed

Valuation Cap

$20,000,000

Discount Rate

10%

Rolling Commitments $

Status
Funded
Reporting Date

05/01/2022

Days Remaining
Funded
% of Min. Goal

743%

% of Max. Goal

37%

Likelihood of Max
Funded
Avg. Daily Raise

$3,201

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Location

Brooklyn, New York

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B/B2C

Margin

Medium

Capital Intensity

High

Business Type

Growth

Corvidane, with a valuation of $20 million, is raising funds on Wefunder. The company is developing a novel drug to prevent heart attacks, strokes, and liver transplants from NASH. The drug Corvida is an innovative approach to treating heart and liver diseases and is built on strong preclinical science. It is safe, contains Omega-7 and Omega-9, and works by improving lipid metabolism. Paresh Soni and Damion Boyer founded Corvidane in July 2014. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1,000,000. The campaign proceeds will be used for operations, toxicology study, market research, and manufacturing.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-33,665

$-39,724

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$2,738

$12,851

Accounts Receivable

$0

$0

Total Assets

$69,379

$67,875

Short-Term Debt

$80,607

$64,755

Long-Term Debt

$0

$0

Total Liabilities

$80,607

$64,755

Financials as of: 01/04/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Corvidane on Wefunder 2022
$
Platform: Wefunder
Security Type: SAFE
Valuation: $20,000,000

Follow company

Follow Corvidane on Wefunder 2022
View on Wefunder (Closed)
Bullish / Bearish
You're Bullish on Corvidane on Wefunder 2022

Thank you for your vote on Corvidane on Wefunder 2022

Bullish / Bearish
You're Bearish on Corvidane on Wefunder 2022

Thank you for your vote on Corvidane on Wefunder 2022